Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02221869 · ClinicalTrials.gov registry record · Phase 3

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

A Phase 3 study of Narcolepsy With Cataplexy, sponsored by Jazz Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
106
Enrollment target
20
Study locations

NCT02221869 is a Phase 3 study of Narcolepsy With Cataplexy that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 106 participants. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02221869, a Phase 3 study of Narcolepsy With Cataplexy, has completed, sponsored by Jazz Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
106 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this trial is to assess the efficacy and safety of Xyrem in pediatrics subjects with narcolepsy that includes cataplexy.

Conditions Studied

Interventions

  • DRUG Xyrem

Study Locations (20)

California

  • Miller Children's Hospital - Long Beach - Long Beach
  • SDS Clinical Trials, Inc. - Orange
  • Stanford Sleep Medicine Center - Redwood City

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati
  • University Hospitals Cleveland Medical Center - Cleveland
  • Nationwide Children's Hospital - Columbus

North Carolina

  • Duke Children's Hospital - Durham
  • ARSM Research, LLC - Huntersville

South Carolina

  • SleepMed of SC - Columbia
  • Greenville Health System - Greenville

Other

  • Hospital Robert Debre - Paris
  • Dipartimento di Scienze Biomediche e Biomotorie - Bologna

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Michigan

  • The U-M Sleep Disorders Center - Ann Arbor

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2014-10-01
Est. Completion 2019-01-25
Phase Phase 3

Sponsor

Jazz Pharmaceuticals

128 total trials

What the Registry Record Tells You About NCT02221869

The ClinicalTrials.gov registry entry for NCT02221869 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Narcolepsy With Cataplexy appearing as the primary indexed condition, and to 1 intervention - of which Xyrem is the first listed.

NCT02221869 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Ohio, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02221869 about?

NCT02221869 is a clinical study titled "A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy". The purpose of this trial is to assess the efficacy and safety of Xyrem in pediatrics subjects with narcolepsy that includes cataplexy.

What is the current status of trial NCT02221869?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2014-10-01. Estimated completion is 2019-01-25.

What conditions does trial NCT02221869 study?

This clinical trial studies the following conditions: Narcolepsy With Cataplexy.

What interventions are being tested in trial NCT02221869?

The interventions under investigation include: Xyrem (DRUG).

Who is sponsoring clinical trial NCT02221869?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02221869 being conducted?

This trial has 20 study locations across California, Illinois, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Narcolepsy With Cataplexy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.